IEX · Idex
28 filings
IEX 10-K Annual Reports
Idex - 28 annual reports
IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 28, 2016
- 8-K · Feb 3, 2016
- 8-K · Feb 10, 2016
- 10-K · Feb 19, 2016
- 8-K · Feb 19, 2016
- 8-K · Mar 18, 2016
- 8-K · Apr 12, 2016
- 8-K · Apr 19, 2016
- 10-Q · Apr 25, 2016
- 8-K · Apr 25, 2016
- 8-K · Jun 15, 2016
- 8-K · Jul 19, 2016
- 8-K · Jul 25, 2016
- 8-K · Jul 28, 2016
- 10-Q · Aug 1, 2016
- 8-K · Sep 2, 2016
- 8-K · Oct 18, 2016
- 8-K · Oct 21, 2016
- 10-Q · Oct 25, 2016
- 8-K · Nov 8, 2016
- 8-K · Jan 4, 2017
- 8-K · Jan 31, 2017
- 8-K · Feb 2, 2017
- 10-K · Feb 23, 2017
- 8-K · Feb 23, 2017
- 8-K/A · Mar 8, 2017
- 8-K · Apr 20, 2017
- 8-K · Apr 25, 2017
- 10-Q · Apr 26, 2017
- 8-K · Apr 27, 2017
- 8-K · Jul 26, 2017
- 10-Q · Jul 26, 2017
- 8-K · Jul 28, 2017
- 8-K · Oct 17, 2017
- 8-K · Oct 20, 2017
- 10-Q · Oct 23, 2017
- 8-K · Jan 2, 2018
- 8-K · Jan 30, 2018
- 8-K · Feb 2, 2018
- 10-K · Feb 22, 2018
- 8-K · Apr 30, 2018
- 8-K · Apr 30, 2018
- 10-Q · Apr 30, 2018
- 8-K · May 3, 2018
- 8-K · Jul 25, 2018
- 10-Q · Jul 25, 2018
- 8-K · Jul 30, 2018
- 8-K · Oct 24, 2018
- 10-Q · Oct 24, 2018
- 8-K · Jan 30, 2019
- 10-K · Feb 28, 2019
- 10-Q · Apr 26, 2019
- 8-K · Apr 26, 2019
- 8-K · May 14, 2019
- 8-K · Jun 4, 2019
- 8-K · Jun 18, 2019
- 10-Q · Jul 26, 2019
- 8-K · Jul 26, 2019
- 10-Q · Oct 30, 2019
- 8-K · Oct 30, 2019
- 8-K · Jan 30, 2020
- 10-K · Feb 21, 2020
- 8-K · Feb 26, 2020
- 8-K · Apr 24, 2020
- 10-Q · Apr 24, 2020
- 8-K · Apr 29, 2020
- 8-K · May 13, 2020
- 10-Q · Jul 24, 2020
- 8-K · Jul 24, 2020
- 8-K · Oct 28, 2020
- 8-K · Oct 28, 2020
- 10-Q · Oct 28, 2020
- 8-K · Jan 13, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 4, 2021
- 8-K/A · Feb 10, 2021
- 10-K · Feb 25, 2021
- 8-K · Feb 26, 2021
- 8-K · Apr 28, 2021
- 8-K · Apr 28, 2021
- 10-Q · Apr 28, 2021
- 8-K · May 10, 2021
- 8-K · May 14, 2021
- 8-K · May 18, 2021
- 8-K · May 28, 2021
- 8-K · Jun 17, 2021
- 8-K · Jun 21, 2021
- 8-K · Jul 2, 2021
- 8-K · Jul 28, 2021
- 10-Q · Jul 28, 2021
- 8-K · Aug 26, 2021
- 10-Q · Oct 27, 2021
- 8-K · Oct 27, 2021
- 8-K · Feb 2, 2022
- 8-K · Feb 8, 2022
- 10-K · Feb 24, 2022
- 8-K · Feb 28, 2022
- 10-Q · Apr 27, 2022
- 8-K · Apr 27, 2022
- 8-K · May 10, 2022
- 8-K · Jun 16, 2022
- 10-Q · Jul 27, 2022
- 8-K · Jul 27, 2022
- 8-K · Sep 13, 2022
- 8-K · Sep 22, 2022
- 8-K · Oct 26, 2022
- 10-Q · Oct 26, 2022
- 8-K · Nov 2, 2022
- 8-K · Nov 17, 2022
- 8-K · Nov 18, 2022
- 8-K · Dec 16, 2022
- 8-K · Feb 1, 2023
- 10-K · Feb 23, 2023
- 10-Q · Apr 27, 2023
- 8-K · Apr 27, 2023
- 8-K · May 31, 2023
- 8-K · Jun 14, 2023
- 10-Q · Jul 27, 2023
- 8-K · Jul 27, 2023
- 8-K · Aug 30, 2023
- 8-K · Aug 30, 2023
- 8-K · Oct 25, 2023
- 8-K · Oct 26, 2023
- 10-Q · Oct 26, 2023
- 8-K · Feb 7, 2024
- 10-K · Feb 22, 2024
- 10-Q · Apr 24, 2024
- 8-K · Apr 24, 2024
- 8-K · May 8, 2024
- 8-K · Jul 23, 2024
- 8-K · Aug 1, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 8, 2024
- 8-K · Aug 21, 2024
- 8-K · Sep 5, 2024
- 10-Q · Oct 30, 2024
- 8-K · Oct 30, 2024
- 8-K · Feb 4, 2025
- 8-K · Feb 20, 2025
- 10-K · Feb 20, 2025
- 8-K · May 1, 2025
- 10-Q · May 1, 2025
- 8-K · May 12, 2025
- 8-K · May 21, 2025
- 10-Q · Jul 30, 2025
- 8-K · Jul 30, 2025
- 8-K · Sep 18, 2025
- 8-K · Oct 29, 2025
- 10-Q · Oct 29, 2025
- 8-K · Dec 4, 2025
- 8-K · Feb 4, 2026
- 8-K · Feb 9, 2026
- 10-K · Feb 19, 2026
- 8-K · Apr 29, 2026
- 10-Q · Apr 29, 2026
- 8-K · May 8, 2026
- 8-K · Jul 29, 2026
- 10-Q · Jul 29, 2026
- 8-K · Aug 17, 2026
- 8-K · Sep 3, 2026
- 8-K · Oct 28, 2026
- 10-Q · Oct 28, 2026
- 2025Feb 19, 2026
Idex Annual Report, Year Ended Dec 31, 2025
IDEX Corporation reported record net sales of $3,457.5 million for 2025, up 6% from $3,268.8 million in 2024, with organic sales growth of 1%. Reported diluted EPS attributable to IDEX was $6.41, down from $6.64, while adjusted diluted EPS rose to $7.95 from $7.89. Management attributed the year's results to positive price across all segments and productivity gains from restructuring and cost containment, offset by lower volumes in the FMT and FSDP segments, higher interest expense, a higher effective tax rate of 23.7%, and higher acquisition-related amortization of $130.7 million. Cash generation remained strong, with operating cash flow of $680.4 million and free cash flow of $616.8 million. The company returned $248 million through share repurchases and $213 million in dividends. Cash and cash equivalents were $580.0 million, total borrowings were $1,829.8 million, and the Revolving Facility had $568.6 million of net availability at year-end. Covenant calculations showed an interest coverage ratio of 13.13 to 1 and a leverage ratio of 1.96 to 1, against required levels of 3.0 to 1 and 3.50 to 1, respectively. Looking ahead, management expects continued growth in HST, supported by data center, semiconductor, space and defense, and food and beverage and pharmaceutical demand. Industrial and automotive markets have not yet recovered, core industrial markets in FMT are tracking flat, and near-term headwinds are expected to persist in FSDP, particularly in Fire & Safety outside the United States and in Dispensing capital spending. The company also reported that Mr. Gillen joined as Senior Vice President and Chief Financial Officer in January 2026.
- 2024Feb 20, 2025
Idex Annual Report, Year Ended Dec 31, 2024
IDEX Corporation reported net sales of $3,268.8 million for 2024, essentially flat against $3,273.9 million in 2023, with organic net sales down 2% offset by a 2% contribution from acquisitions net of divestitures. Diluted EPS attributable to IDEX was $6.64, down 15% from $7.85, while adjusted diluted EPS was $7.89, down 4% from $8.22. Operating cash flow was $668.1 million, down 7%, and free cash flow was $603.0 million, down 4%. The Company's Health & Science Technologies segment saw the most pressure, with organic net sales down 10% amid cyclical softness in life sciences and semiconductor markets, while Fire & Safety/Diversified Products grew 4% in net sales. The defining event of 2024 was the acquisition of Mott Corporation on September 5, 2024, for cash consideration of $986.2 million, net of cash acquired. The Company funded it with $211.9 million of cash on hand, $279.3 million of Revolving Facility borrowings, and $495.0 million of net proceeds from a $500 million 4.950% Senior Notes offering due 2029. Mott is described as the Company's largest acquisition to date. Total borrowings rose to $1,971.3 million at December 31, 2024, from $1,333.3 million a year earlier, and the Company reported a 2.20 to 1 leverage ratio for covenant purposes against a 3.50 to 1 maximum. Looking ahead, management expects growth in HST from therapeutics, nutrition, satellite communications and datacenter-related energy demand, with semiconductor demand delayed until the second half of 2025. In early 2025 the Company began organizational changes and expects approximately $21 million to $25 million of severance-related restructuring charges. The Company also repurchased 256,159 shares for $50.0 million in February 2025, leaving $539.7 million of authorization remaining at year-end 2024.
- 2023Feb 22, 2024
Idex Annual Report, Year Ended Dec 31, 2023
IDEX Corporation (IEX) reported 2023 net sales of $3,273.9 million, up 3% from $3,181.9 million in 2022, with organic net sales declining 1%. Net income attributable to IDEX was $596.1 million, up 2%, and diluted EPS was $7.85 versus $7.71. Adjusted EBITDA rose 2% to $899.6 million, and the company generated record free cash flow of $626.8 million on operating cash flow of $716.7 million. Growth was driven by a 5% contribution from acquisitions net of divestitures and price capture, partially offset by lower volumes, particularly in the Health & Science Technologies segment, as customers destocked inventory. The company operates three reportable segments: Fluid & Metering Technologies (42% of segment Adjusted EBITDA), Health & Science Technologies (37%), and Fire & Safety/Diversified Products (21%). During 2023 IDEX acquired Iridian Spectral Technologies for $109.8 million and STC Material Solutions for $202.0 million, and sold Micropump for $110.3 million, recording a pre-tax gain of $93.8 million. Total borrowings were $1,333.3 million at year-end, with cash and cash equivalents of $534.3 million, and the company was in compliance with its financial covenants, with an interest coverage ratio of 18.43 to 1 and a leverage ratio of 1.45 to 1. Management stated that the majority of its businesses were seeing stable demand and early signs of improvement, particularly in Fluid & Metering Technologies, while life sciences and analytical instrument markets were not yet showing near-term recovery. The Dispensing reporting unit is expected to contract in 2024 following completion of a North American fleet refreshment cycle in 2023.
- 2022Feb 23, 2023
Idex Annual Report, Year Ended Dec 31, 2022
IDEX Corporation's 2022 Form 10-K reports a record year in sales, driven by robust demand, with net sales of $3,181.9 million, up 15% from $2,764.8 million in 2021. Organic sales rose 13%, and net income attributable to IDEX was $586.9 million, up 31%. Diluted EPS was $7.71, compared with $5.88 in 2021. Adjusted EBITDA reached $884.2 million, up 16%, with an Adjusted EBITDA margin of 27.9%. Management attributes the results to price capture amid inflation, execution, and the acquisition of Nexsight, KZValve and Muon Group during 2022. Cash flow from operations was $557.4 million, down from $565.3 million, as higher earnings were more than offset by increased working capital investment. Free cash flow was $489.4 million, or 79.2% of adjusted net income attributable to IDEX. Cash and cash equivalents fell to $430.2 million, and total borrowings rose to $1,477.8 million. The company repurchased 795,423 shares for $148.1 million and paid $177.4 million in dividends. Investing outflows of $917.2 million reflected acquisitions, including Muon Group for $713.0 million in cash. The Company stated it expects to refinance or repay its $100.0 million 3.20% Senior Notes due June 2023 using Revolving Facility capacity, and it reports a net available revolver borrowing capacity of $714.4 million. For 2023, management's stated priorities are foundational execution, building global teams, and capital deployment, with $1.5 billion deployed over the last two years on growth opportunities and a stated expectation of a high-quality acquisition pipeline. Credit ratings are BBB (S&P), Baa2 (Moody's) and BBB+ (Fitch), and the company reports compliance with its financial covenants.
- 2021Feb 24, 2022
Idex Annual Report, Year Ended Dec 31, 2021
IDEX Corporation reported a record year for 2021, with net sales of $2,764.8 million, up 18% from $2,351.6 million in 2020, and organic sales up 12%. Operating income rose 22% to $637.0 million, and diluted EPS attributable to IDEX was $5.88, up $0.94, or 19%. Adjusted diluted EPS was $6.30, up 21%. Operating margin expanded 90 basis points to 23.0%, and the company cited volume leverage and favorable price/cost as drivers, partly offset by higher amortization and acquisition-related inventory step-up charges. Cash flow from operating activities was $565.3 million, flat year over year, as volume-driven working capital increases offset strong operating results. Free cash flow was $492.6 million, down from $517.7 million in 2020. Investing outflows rose to $698.1 million, mainly due to the ABEL and Airtech acquisitions. Cash and cash equivalents ended the year at $855.4 million, and total debt was $1,200.1 million, all fixed rate. The company had no revolver borrowings at year-end and $792.8 million of net available revolver capacity. Covenant compliance was reported, with an interest coverage ratio of 20.12 to 1 and a leverage ratio of 1.52 to 1. The company deployed record capital in 2021, including the purchases of ABEL for $106.3 million and Airtech for $471.0 million, and expects to close the pending Nexsight acquisition for $120.0 million by the end of the first quarter of 2022. Management plans to deploy additional capital for acquisitions and organic investments in 2022, and it increased the quarterly dividend to $0.54 per share, a dividend payment total of $161.1 million in 2021.
- 2020Feb 25, 2021
Idex Annual Report, Year Ended Dec 31, 2020
IDEX Corporation's 2020 Form 10-K reports net sales of $2.35 billion, down 6% from $2.49 billion in 2019, with organic sales down 9%, partially offset by a 3% increase from acquisitions (Flow MD and Velcora). Operating income fell 10% to $520.7 million, and operating margin declined to 22.1% from 23.2%. Net income decreased 11% to $377.8 million, and diluted EPS was $4.94 versus $5.56. Adjusted EPS, which excludes restructuring, inventory step-up, and debt redemption charges, was $5.19 compared with $5.80. Management attributes the declines mainly to COVID-19, with end markets improving from the third quarter of 2020 through the fourth quarter. Cash flow from operations rose 7.8% to $569.3 million, supported by working capital performance. The company ended the year with $1,025.9 million of cash and cash equivalents and an $792.8 million net available borrowing capacity under its revolving facility. It issued $500.0 million of 3.0% Senior Notes due 2030 and redeemed $300.0 million of 4.5% Senior Notes. Total borrowings were $1,050.2 million, all fixed rate, and the company reported compliance with its financial covenants. Share repurchase authorization remaining was $712.0 million. Subsequent to year end, IDEX agreed on January 8, 2021 to acquire Abel Pumps, L.P. and certain affiliates for $103.5 million in cash, expected to close by the end of the first quarter of 2021, subject to regulatory approval. The filing also reports that the company has three reportable segments and 13 platforms, and that its internal control over financial reporting was effective as of December 31, 2020.
- 2019Feb 21, 2020
Idex Annual Report, Year Ended Dec 31, 2019
IDEX Corporation's 2019 Form 10-K reports net sales of $2,494,573 thousand ($2.49 billion), essentially flat versus $2,483,666 thousand in 2018, reflecting a 1% increase in organic sales and a 1% increase from acquisitions, offset by a 2% unfavorable foreign currency impact. Operating income rose 2% to $579.0 million, with operating margin of 23.2%, up 30 basis points. Net income increased 4% to $425.5 million, and diluted EPS was $5.56, up $0.27 from $5.29. Excluding $21.0 million of restructuring expense and a $3.3 million fair value inventory step-up charge, adjusted operating income grew 4% to $603.4 million and adjusted EPS rose 7% to $5.80. Cash flow from operations increased to $528.1 million, and cash and cash equivalents ended the year at $632.6 million, of which $350.9 million was held outside the United States. Capital expenditures were $50.9 million. The company repurchased $54.7 million of stock in 2019, versus $173.9 million in 2018, and had $322.3 million of repurchase authorization remaining. Dividends declared rose to $2.00 per share from $1.72. The company acquired Velcora for $87.2 million in cash plus $51.1 million of assumed debt, which was later retired. Its $800.0 million revolving facility had no balance outstanding at year end, and total borrowings were $850.6 million, substantially all fixed rate. Subsequent to year end, IDEX agreed on January 29, 2020 to acquire Flow Management Devices, LLC for $125 million in cash, with closing expected by the end of the first quarter of 2020. The filing also discloses a wind-down of one Health & Science Technologies business after the loss of its largest customer, which drove $9.7 million of impairment charges within restructuring expense.
- 2018Feb 28, 2019
Idex Annual Report, Year Ended Dec 31, 2018
IDEX Corporation (IEX) reported 2018 net sales of $2.48 billion, up 9% from $2.29 billion in 2017, with an 8% increase in organic sales and a 1% favorable impact from foreign currency translation. Operating income rose 13% to $569.1 million and operating margin reached 22.9%, up 90 basis points. Net income increased 22% to $410.6 million, and diluted EPS was $5.29, up $0.93 from $4.36. Excluding restructuring expense in 2018 and the 2017 gain on the sale of a business and restructuring costs, adjusted operating income was $581.2 million (up 16%), adjusted net income was $419.6 million (up 26%), and adjusted EPS was $5.41. The company operates three reportable segments: Fluid & Metering Technologies (38% of 2018 sales), Health & Science Technologies (36%), and Fire & Safety/Diversified Products (26%). Across its 13 platforms, approximately 51% of 2018 sales were to customers outside the U.S. Cash flow from operations was $479.3 million, cash and equivalents totaled $466.4 million, and total borrowings were $851.1 million. The company repurchased 1.3 million shares for $173.9 million in 2018, and $377.0 million remained under its repurchase authorization at year end. For 2019, management projected 4 to 5 percent organic revenue growth and full-year EPS in the range of $5.60 to $5.80. The filing notes risks including trade tensions and tariffs, foreign currency movements, acquisition integration, and a goodwill and intangible asset base of $1,698.0 million and $383.3 million, respectively, at December 31, 2018.
- 2017Feb 22, 2018
Idex Annual Report, Year Ended Dec 31, 2017
IDEX Corporation's 2017 Form 10-K reports net sales of $2,287,312 thousand ($2.29 billion), up 8% from $2,113,043 thousand in 2016, with organic sales up 6% and acquisitions/divestitures adding 2%. Operating income rose 22% to $502,556 thousand, and operating margin was 22.0%, up 250 basis points. Net income increased 24% to $337,257 thousand, and diluted EPS was $4.36, compared with $3.53 in 2016. Adjusted EPS, which excludes restructuring, divestiture gains and losses, and a 2016 pension settlement, was $4.31, up from $3.75. Adjusted EBITDA was $583,560 thousand, flat with 2016 in margin terms at 25.5%. The company operates three reportable segments: Fluid & Metering Technologies (38% of 2017 sales), Health & Science Technologies (36%), and Fire & Safety/Diversified Products (26%). Roughly 49% of 2017 sales were to customers outside the U.S. Cash flow from operations was $432.8 million, and capital expenditures were $43.9 million. Total borrowings declined to $862.2 million from $1,020.9 million, and shareholders' equity rose to $1,886.5 million. Management projects approximately 5% organic revenue growth and full-year 2018 EPS of $4.90 to $5.10. The 2017 results include a $9.3 million gain on the Faure Herman divestiture, $8.5 million of restructuring expense, and a provisional net $0.1 million tax benefit from the Tax Cuts and Jobs Act, which included a $30.3 million transition tax expense and a $40.6 million deferred tax benefit. Goodwill and intangibles totaled $1,704.2 million and $414.7 million, respectively, against $3,399.6 million of total assets.
- 2016Feb 23, 2017
Idex Annual Report, Year Ended Dec 31, 2016
IDEX Corporation's 2016 Form 10-K reports net sales of $2.11 billion, up 5% from $2.02 billion in 2015, driven by a 7% contribution from acquisitions and divestitures, offset by a 1% decrease in organic sales and a 1% decrease from foreign currency translation. Operating income was $405.8 million, down 6%, with operating margin of 19.2% (down 220 basis points). Net income decreased 4% to $271.1 million, and diluted EPS was $3.53. Excluding restructuring costs, a $3.6 million pension settlement charge and a $22.3 million loss on sale of businesses, adjusted EPS was $3.75, up 6% from $3.55. Management projects 1 to 2 percent organic growth in 2017 and full-year 2017 EPS of $3.87 to $3.95. The company made four acquisitions in 2016, including Akron Brass ($221.4 million), AWG Fittings ($47.5 million) and SFC Koenig ($241.1 million), and completed four divestitures. Cash flow from operations rose to $399.9 million, and year-end total borrowings increased to $1.02 billion after issuing $200 million of senior notes. Shareholders' equity was $1.54 billion and goodwill was $1.63 billion, which the filing notes is a significant portion of total assets. During 2016 the company repurchased $55.0 million of stock, leaving $580 million of authorization. Dividends declared rose to $1.36 per share from $1.28. Management reported that internal control over financial reporting was effective as of December 31, 2016, and that the asbestos-related lawsuits naming the company are not expected to have a material adverse effect.
- 2015Feb 19, 2016
Idex Annual Report, Year Ended Dec 31, 2015
IDEX Corporation's annual report for fiscal 2015 shows net sales of $2.02 billion, down (6)% from $2.15 billion in 2014, driven by a 4% decrease in organic sales and a 4% unfavorable foreign currency effect, partly offset by a 2% contribution from acquisitions. Operating income was $431.7 million, flat year over year, with operating margin rising 130 basis points to 21.4%, aided by an $18.1 million gain on the sale of the Ismatec product line. Net income rose 1% to $282.8 million and diluted EPS increased to $3.62 from $3.45. Adjusted for $11.2 million of restructuring costs and the Ismatec gain, adjusted EPS was $3.55, down 1% from $3.57. Management stated that continued global economic contraction will pressure its end markets, creating an unstable growth environment in 2016, and anticipates flat organic growth and full-year 2016 EPS of $3.60 to $3.70. Segment performance was mixed: Fluid & Metering Technologies sales fell 4% with operating margin of 23.8%, Health & Science Technologies sales fell 2% while operating margin improved to 21.4%, and Fire & Safety/Diversified Products sales fell 16% with operating margin rising to 27.3%. Cash flow from operations was $360.3 million, and the company repurchased 2.8 million shares for $210.5 million during 2015. Subsequent to year-end, IDEX agreed on February 4, 2016 to acquire Akron Brass Holding Corp. for $224.2 million in cash, which had trailing twelve-month revenues of approximately $120 million. Balance sheet leverage remained moderate, with total borrowings of $847.4 million and shareholders' equity of $1.44 billion at year-end. The company was in compliance with its revolving facility covenants, reporting an interest coverage ratio of 12.73 to 1 and a leverage ratio of 1.63 to 1 against maximums of 3.50 to 1. Goodwill and intangible assets together totaled $1.68 billion, and the company noted that the IOP and Valves reporting units had the least headroom in its October 31, 2015 impairment test.
- 2014Feb 23, 2015
Idex Annual Report, Year Ended Dec 31, 2014
IDEX Corporation (IEX) reported 2014 net sales of $2.15 billion, up 6% from $2.02 billion in 2013, with organic sales up 5%. Operating income rose to $431.2 million (operating margin 20.1%), and net income increased 9% to $279.4 million. Diluted EPS was $3.45, up $0.36 from $3.09. Excluding $13.7 million of restructuring costs, adjusted operating income was $444.9 million and adjusted EPS was $3.57. Management expects 2015 organic revenue growth of 1 to 2 percent and EPS of $3.65 to $3.75, citing a soft European market and volatile Asia. The company operates three reportable segments: Fluid & Metering Technologies (42% of 2014 sales, 43% of operating income), Health & Science Technologies (35% of sales, 31% of operating income), and Fire & Safety/Diversified Products (23% of sales, 26% of operating income). Roughly 50% of 2014 sales were to customers outside the U.S. Cash from operations was $368.0 million, and capital expenditures were $48.0 million. Total borrowings were $863.9 million, and the company repurchased 3.0 million shares for $222.5 million during 2014. Remaining repurchase authorization was $545 million at year-end. The filing also discloses goodwill of $1.32 billion and intangible assets of $271.2 million, which together make up a significant share of total assets of $2.91 billion. Management noted that the IOP reporting unit had the thinnest headroom, with fair value greater than 15% above carrying value. The company is also a defendant in asbestos-related lawsuits, for which no provision has been made beyond insurance deductibles.
- 2013Feb 13, 2014
Idex Annual Report, Year Ended Dec 31, 2013
IDEX Corporation (IEX) reported net sales of $2,024.1 million for 2013, up 4% from $1,954.3 million in 2012, with organic sales up 2%. Operating income rose to $395.5 million from $128.2 million, a 208% increase, which the filing attributes largely to the absence of the $198.5 million asset impairment charge and $32.5 million of restructuring charges recorded in 2012. Net income was $255.2 million, or $3.09 per diluted share, compared with $37.6 million, or $0.45 per diluted share, in 2012. Operating margin improved to 19.5% from 6.6%. The company operates three reportable segments: Fluid & Metering Technologies (43% of 2013 sales and 47% of operating income), Health & Science Technologies (35% of sales and 30% of operating income), and Fire & Safety/Diversified Products (22% of sales and 23% of operating income). Approximately 51% of 2013 sales were to customers outside the U.S. Cash flow from operations was $401.5 million, and cash and cash equivalents were $439.6 million at year-end. Total borrowings were $773.9 million, and the company repurchased 2.9 million shares for $167.5 million during 2013. Management guided to 3% to 5% organic revenue growth and EPS of $3.33 to $3.43 for 2014. Investors should note the company's heavy reliance on acquisitions and goodwill: goodwill and intangible assets totaled $1,349.5 million and $311.2 million, respectively, representing a large share of total assets of $2,887.6 million. The filing also discloses that in 2012 the company recorded impairments within its IOP and WST units, and that the IOP unit's fair value remained only modestly above carrying value at the 2013 annual test.
- 2012Feb 21, 2013
Idex Annual Report, Year Ended Dec 31, 2012
IDEX Corporation's 2012 Form 10-K reports net sales of $1,954,258 thousand, up 6% from $1,838,451 thousand in 2011, with organic sales up 3%. Operating income fell 58% to $128,218 thousand, driven by a $198,519 thousand asset impairment charge recorded in the fourth quarter, largely tied to the IOP (Optics & Photonics) and WST (Water Services & Technology) platforms. Net income decreased 81% to $37,630 thousand, and diluted EPS was $0.45 versus $2.32 in 2011. The effective tax rate rose to 56.3%, mainly due to the nonrecurring impairment charge, which the filing says increased the rate by 26.9%. By segment, Fluid & Metering Technologies generated 43% of 2012 sales and 82% of operating income, Health & Science Technologies contributed 35% of sales with a negative operating income of $(62,835) thousand, and Fire & Safety/Diversified Products provided 22% of sales and 53% of operating income. Cash flow from operations rose to $326,180 thousand, and cash and cash equivalents were $318,864 thousand at year end. Total borrowings were $786,576 thousand, and the company stated it was in compliance with its financial covenants, with an interest coverage ratio of 10.05 to 1 and a leverage ratio of 1.92 to 1. For 2013, management forecast fully diluted EPS of $2.85 to $2.95. The company repurchased 2.2 million shares for $89.6 million during 2012, and the board increased the repurchase authorization by $200.0 million in October 2012.
- 2011Feb 24, 2012
Idex Annual Report, Year Ended Dec 31, 2011
IDEX Corporation's 2011 Form 10-K reports net sales of $1,838.5 million, up 22% from $1,513.1 million in 2010, with organic sales up 9%, 11% from seven acquisitions, and 2% favorable currency translation. Operating income rose to $304.7 million (16.6% of sales) and net income increased 23% to $193.9 million, with diluted EPS of $2.32 versus $1.90. Growth was driven largely by the CVI Melles Griot acquisition in June 2011 for $393.3 million in cash, funded mainly by revolver borrowings and the December 2011 issuance of $350.0 million 4.2% senior notes. Total borrowings rose to $808.8 million from $527.9 million, while the interest coverage ratio was 12.4 to 1 and the leverage ratio 2.2 to 1 against covenant limits of 3.0 and 3.25. The company's four segments were Fluid & Metering Technologies (44% of sales, 45% of operating income), Health & Science Technologies (34% of sales, 31% of operating income), Dispensing Equipment (6% of sales, 4% of operating income), and Fire & Safety/Diversified Products (16% of sales, 20% of operating income). Roughly 53% of 2011 sales were to customers outside the U.S. For 2012, management expects mid-single digit organic growth and fully diluted EPS of $2.74 to $2.82. Operating cash flow was $217.2 million, and capital expenditures were $34.5 million. Goodwill of $1,431.4 million and intangible assets of $382.2 million together represent a substantial share of total assets of $2,836.1 million, a risk the filing highlights. The company also disclosed a $125.0 million share repurchase authorization, with no shares repurchased in 2011 or 2010, and an asbestos-related lawsuit exposure that management does not currently believe will have a material adverse effect.
- 2010Feb 25, 2011
Idex Annual Report, Year Ended Dec 31, 2010
IDEX Corporation's 2010 Form 10-K reports net sales of $1.51 billion, up 14% from $1.33 billion in 2009, with organic sales up 12% and acquisitions contributing 3%. Operating income rose 35% to $249.1 million, operating margin expanded to 16.5% from 13.9%, and net income increased 39% to $157.1 million. Diluted EPS was $1.90, compared with $1.40 in 2009. Gross margin improved 160 basis points to 40.9%, driven by higher volume, restructuring-related cost reductions and product mix. The company operates four reportable segments: Fluid & Metering Technologies (48% of 2010 sales, 44% of operating income), Health & Science Technologies (26% and 28%), Dispensing Equipment (8% and 7%), and Fire & Safety/Diversified Products (18% and 21%). Operating cash flow was $184.5 million, with capital expenditures of $32.8 million. Cash and cash equivalents rose to $235.1 million at year end, while total borrowings increased to $527.9 million after the issuance of $300.0 million of 4.5% Senior Notes due 2020 and €81.0 million of 2.58% Senior Euro Notes due 2015. The company was in compliance with its financial covenants at December 31, 2010. For 2011, the filing states that IDEX expects mid-to-high single-digit organic growth, approximately 4% acquisition-related growth, and fully diluted EPS of $2.23 to $2.33. Subsequent events include the January 2011 acquisition of Advanced Thin Films (approximately $32.0 million cash) and a merger agreement to acquire Microfluidics International at $1.35 per share in cash. The Credit Facility and Term Loan both mature on December 21, 2011, and management intends to enter a new revolving credit facility during 2011.
- 2009Mar 1, 2010
Idex Annual Report, Year Ended Dec 31, 2009
IDEX Corporation's 2009 Form 10-K, filed for the year ended December 31, 2009, reports net sales of $1.33 billion, down 11% from $1.49 billion in 2008, driven by a 14% decrease in organic sales and 2% unfavorable foreign currency translation, partly offset by a 5% increase from four acquisitions completed in October 2008. Operating income fell to $184.9 million from $206.0 million, and net income declined to $113.4 million, or $1.40 diluted EPS, from $127.0 million, or $1.53. Organic sales declined in all four reporting segments. Gross margin slipped to 39.3% from 40.1%, and the company recorded $12.1 million of restructuring expenses in 2009 with a further $4.0 to $5.0 million expected in 2010. The company's balance sheet strengthened over the year. Total borrowings fell to $400.1 million from $554.0 million, and shareholders' equity rose to $1.27 billion from $1.14 billion. Cash flow from operating activities was $212.5 million, against capital expenditures of $25.5 million. Working capital was $262.0 million with a current ratio of 2.4 to 1. Management states the company has not experienced liquidity issues and expects its liquidity to be sufficient for the next twelve months. No shares were repurchased in 2009, and $75.0 million remained under the $125.0 million repurchase authorization. The company reports goodwill of $1.18 billion and intangible assets of $281.4 million, about two-thirds of total assets of $2.10 billion. A $30.1 million goodwill impairment recorded in 2008 at Fluid Management is discussed, and management notes that a 10% decline in fair value at the Banjo or Water reporting units could trigger impairment charges, with $288.7 million of goodwill at those two units. The company also disclosed a fourth-quarter 2009 change from LIFO to FIFO inventory accounting, applied retrospectively, which reduced 2009 net income by $2.5 million.
- 2008Mar 2, 2009
Idex Annual Report, Year Ended Dec 31, 2008
IDEX Corporation, a Delaware corporation, describes itself as an applied solutions company specializing in fluid and metering technologies, health and science technologies, dispensing equipment, and fire, safety and other diversified products. For 2008, net sales were $1,489.5 million, up 10% from $1,358.6 million in 2007. Acquisitions made since 2007 contributed 9 percentage points of growth, foreign currency translation 1%, and organic sales were flat. Operating income fell 17% to $212.4 million, reflecting an $30.1 million goodwill impairment at Fluid Management Americas and $18.0 million of restructuring expenses. Diluted EPS from continuing operations was $1.60, down from $1.90 in 2007, and net income was $131.4 million versus $155.1 million. The balance sheet grew with acquisitions. Total assets were $2,176.3 million, goodwill $1,167.1 million and intangible assets $303.2 million. Total borrowings rose to $554.0 million from $454.7 million, and borrowings as a percent of capitalization increased to 32.2% from 28.1%. The company reported working capital of $286.0 million and a current ratio of 2.3 to 1, and operating cash flow from continuing operations was $224.1 million. Management stated the company had not experienced liquidity issues and expected liquidity to be sufficient over the next twelve months. Capital expenditures were $27.8 million, and the company repurchased 2.3 million shares for $50.0 million under a $125.0 million authorization. Investors should weigh the flat organic growth, the margin compression from gross margin falling to 40.5% from 41.8%, and the Dispensing Equipment segment's operating loss of $10.6 million against the company's acquisition-driven expansion. The filing also notes a $1.2 million-scale sensitivity to a 50 basis point interest rate move on floating debt, and that two Fluid & Metering Technologies reporting units carrying $204.2 million of goodwill could face impairment if fair value fell 10%.
- 2007Feb 29, 2008
Idex Annual Report, Year Ended Dec 31, 2007
IDEX Corporation (NYSE and Chicago Stock Exchanges: IEX) reported record 2007 results, with net sales of $1.36 billion, up 18% from $1.15 billion in 2006. Organic sales grew 6%, seven acquisitions added 9%, and foreign currency translation added 3%. Operating income rose 17% to $255.1 million, with operating margin flat at 18.8%. Income from continuing operations increased 17% to $155.9 million, and diluted EPS from continuing operations was $1.90. Net income was $155.1 million, or $1.89 diluted EPS, after a $0.7 million loss from discontinued operations. Gross margin improved 50 basis points to 41.8%, which the company attributes mainly to strategic sourcing and operational excellence initiatives. SG&A rose to $313.4 million, reflecting $33.1 million from acquisitions. Total debt was $454.7 million at year end, with about 67% floating-rate. Cash flow from continuing operations rose 24% to $198.1 million. Working capital was $438.2 million and the current ratio was 3.2 to 1. The company was in compliance with its two financial covenants. In early January 2008, IDEX completed the acquisition of ADS, LLC for about $160 million in cash, financed by its Credit Facility. ADS had 2007 revenues of approximately $70 million and will operate within the Fluid and Metering Technologies Segment. The company also said it expects continued strong demand in infrastructure and process control markets in 2008, offset in part by softness in the North American housing and fire suppression markets.
- 2006-AMay 1, 2007
Idex Annual Report (Amendment), Year Ended Dec 31, 2006
IDEX Corporation (NYSE and Chicago Stock Exchanges: IEX) filed this Form 10-K/A (Amendment No. 1) for the fiscal year ended December 31, 2006. The amendment was filed solely to amend Exhibit 13 to add language required by New York Stock Exchange certification disclosures. It does not amend, update or change the financial statements or any other items or disclosures in the original filing, so the financial results are not restated here. The filing states that the registrant is a large accelerated filer and a well-known seasoned issuer, incorporated in Delaware and headquartered at 630 Dundee Road, Northbrook, Illinois. The aggregate market value of voting stock held by non-affiliates was $2,495,689,616, based on the June 30, 2006 closing price of $47.20. Shares outstanding were 53,823,941 as of February 15, 2007, net of treasury shares. The Exhibit 13 portions incorporated by reference show a quarterly dividend of $0.15 per share paid on January 31, 2007, approximately 6,700 shareholders at December 31, 2006, and 2006 quarterly stock price ranges. Deloitte & Touche LLP is the independent registered public accounting firm. The 2007 Annual Meeting was scheduled for April 3, 2007.
- 2006Mar 1, 2007
Idex Annual Report, Year Ended Dec 31, 2006
IDEX Corporation's 2006 Form 10-K reports record results across its four reporting segments, which were reorganized in 2006 from three to four: Fluid & Metering Technologies, Health & Science Technologies, Dispensing Equipment, and Fire & Safety/Diversified Products. Net sales rose to $1,154.9 million in 2006 from $1,011.3 million in 2005, with base business sales up 9% and acquisitions contributing 5%. Operating income increased to $217.2 million (18.8% of sales), income from continuing operations rose 23% to $133.7 million, and net income increased 34% to $146.7 million, or $2.72 diluted EPS. New orders totaled $1,184.5 million, up 16%. Growth was supported by five 2006 acquisitions (Airshore, JUN-AIR, Eastern Plastics, Banjo and Toptech) and the sale of the Lubriquip business, which produced a $16.7 million after-tax gain. Halox was classified as a discontinued operation and is being marketed for sale. Total borrowings rose to $362.0 million at year-end, and the company reported compliance with its two financial covenants. Goodwill and intangible assets totaled $912.6 million and $171.4 million, respectively, and management concluded no impairment existed. Key risks cited include international exposure (45% of 2006 sales outside the U.S.), reliance on acquisitions for growth, competitive pressure, and exposure to euro and British pound currency movements. The asbestos-related lawsuits named against IDEX and five subsidiaries are, per management, not expected to have a material adverse effect. The filing also notes that the $150.0 million of 6.875% Senior Notes mature February 15, 2008, and that the company was evaluating its options for repaying them, including potential use of its credit facility.
- 2005Mar 6, 2006
Idex Annual Report, Year Ended Dec 31, 2005
IDEX Corporation's 2005 annual report (Form 10-K filed March 6, 2006) shows record results. Net sales rose to $1,043.3 million from $928.3 million, with orders at a record $1,057.0 million. Operating income reached $182.8 million, an operating margin of 17.5%, and net income was $109.8 million, or $2.08 per diluted share. Cash flow from operating activities reached an all-time high of $144.9 million. The company reports three segments: Pump Products Group (59% of sales, 54% of operating income), Dispensing Equipment Group (18% of sales, 19% of operating income), and Other Engineered Products Group (23% of sales, 27% of operating income). Balance sheet and capital position remained solid. Total assets were $1,244.2 million and shareholders' equity was $823.0 million. Total borrowings fell to $160.0 million from $225.3 million, with borrowings at 16.3% of capitalization versus 24.0% a year earlier. The company had no borrowings under its $600 million Credit Facility at year end. Goodwill totaled $691.9 million, and management determined no impairment existed. International customers accounted for 43% of revenue. The filing also flags risks, including exposure to economic cycles, foreign currency (euro and British pound), acquisition integration, and labor negotiations. Asbestos-related lawsuits name IDEX and five subsidiaries, but management does not believe they will have a material adverse effect, and insurance has covered settlements to date. Kingsley, CEO since March 2005, is to become Chairman effective April 4, 2006, and Dennis K. Williams is retiring as Chairman on that date.
- 2004Feb 28, 2005
Idex Annual Report, Year Ended Dec 31, 2004
IDEX Corporation's 2004 Form 10-K, filed February 28, 2005, reports record results for the year. Orders reached $942.4 million, up 18%, and net sales rose 16% to $928.3 million, with base business sales up 7%. Operating income increased 36% to $149.4 million, operating margin rose to 16.1% from 13.8%, and net income rose 39% to $86.4 million, or $1.68 diluted EPS. Operating cash flow reached an all-time high of $142.3 million. Acquisitions completed in 2004 were Vetter, Systec, Scivex and Dinglee, at total purchase prices of about $170.0 million. The company operates three segments: Pump Products (58% of 2004 sales and 54% of operating income), Dispensing Equipment (18% of sales and 19% of operating income), and Other Engineered Products (24% of sales and 27% of operating income). International customers accounted for 44% of 2004 sales. Total debt rose to $225.3 million from $176.546 million, and shareholders' equity increased to $713.6 million. The company's year-end current ratio was 1.8. The filing discloses asbestos-related lawsuits naming IDEX and nine subsidiaries. Management states that settlements and legal costs have been largely covered by insurance and that it does not believe these claims will have a material adverse effect. Management also says it has limited visibility on future business conditions, and it expects economic conditions to remain favorable.
- 2003Mar 5, 2004
Idex Annual Report, Year Ended Dec 31, 2003
IDEX Corporation reported record orders, sales, and cash flows for 2003, with net sales of $797.9 million, up from $742.0 million in 2002, and net income of $62.4 million, or $1.87 per diluted share, compared with $54.1 million, or $1.67 per share, a year earlier. Operating income rose to $109.9 million from $100.4 million, with operating margin of 13.8% versus 13.5%. Management attributed the gains to higher gross profit from global sourcing and Six Sigma, Kaizen and Lean initiatives, partly offset by higher SG&A expenses. Acquisitions contributed about 2 percentage points of sales growth and foreign currency translation about 5 percentage points, while base business sales rose 1%. The company operates three segments: Pump Products (57% of 2003 sales and 55% of operating income), Dispensing Equipment (20% of both), and Other Engineered Products (23% of sales and 25% of operating income). Total debt fell to $176.5 million at year end from $241.1 million in 2002, and shareholders' equity rose to $592.1 million. Cash flow from operations was $111.7 million, and the filing states that the company expects sufficient cash flow to meet its needs over the next 12 months and the long term. The company also completed the Sponsler and Classic Engineering acquisitions in 2003 and agreed to acquire Manfred Vetter GmbH in January 2004. The filing discloses asbestos-related lawsuits naming IDEX and nine subsidiaries, which the company states are largely covered by insurance and not expected to have a material adverse effect. Management also noted that 2003 SG&A rose to 25.0% of sales from 24.4%, and that the Pump Products Group's operating margin declined to 15.4% from 16.5%.
- 2002-AMar 14, 2003
Idex Annual Report (Amendment), Year Ended Dec 31, 2002
IDEX Corporation filed this Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2002, to amend Part III, Item 12 (Security Ownership of Certain Beneficial Owners and Management) and Item 14 (Controls and Procedures). The filing renumbers the original Item 14 as Item 15. The registrant reports an aggregate market value of voting stock held by non-affiliates of $891,691,395 as of December 31, 2002, and 32,504,959 shares of common stock outstanding (net of treasury shares) as of January 31, 2003. Item 12 incorporates by reference the "Security Ownership" section on pages 8 and 9 of the 2003 Proxy Statement, along with "Proposal 2 -- Approval of the Third Amended and Restated 1996 Stock Option Plan For Non-Officer Key Employees of IDEX Corporation" on pages 16 through 19 of that proxy statement. The amended Item 14 states that the Chief Executive Officer and Chief Financial Officer concluded, based on an evaluation carried out within 90 days before the report date, that the company's disclosure controls and procedures were effective. It also states there were no significant changes in internal controls subsequent to that evaluation. The amendment is signed by Wayne P. Sayatovic, Senior Vice President -- Finance and Chief Financial Officer, and dated March 13, 2003. Certifications under the Sarbanes-Oxley framework were provided by Dennis K. Williams, Chairman, President and Chief Executive Officer, and by Mr. Sayatovic. The filing is limited in scope and does not restate the company's full annual report content.
- 2002Feb 28, 2003
Idex Annual Report, Year Ended Dec 31, 2002
IDEX Corporation (NYSE and Chicago Stock Exchange: IEX) reported 2002 net sales of $742.0 million, up from $726.9 million in 2001, and net income of $54.1 million, or $1.67 per diluted share, versus $32.7 million, or $1.05 per share, in 2001. Operating income rose to $100.4 million from $73.4 million, helped by the absence of goodwill and trademark amortization in 2002 (which had been $14.6 million in 2001) and the lack of a 2001 restructuring charge of $11.2 million. Operating margin was 13.5% compared with 10.1% in 2001. New orders totaled $749.8 million, 5% higher than 2001, but excluding acquisitions and currency, orders were only 1% higher, and management stated it saw no significant market recovery during 2002 and no indication that sluggishness in end markets would change soon. The company operates three segments: Pump Products Group (58% of 2002 sales, 62% of operating income), Dispensing Equipment Group (19% of sales, 16% of operating income), and Other Engineered Products Group (23% of sales, 22% of operating income). Cash flow from operations was $108.4 million and free cash flow was $89.1 million. Total debt fell to $241.1 million from $291.8 million, and shareholders' equity rose to $506.8 million from $401.1 million, reflected in a $50.8 million common stock offering in 2002. Management said the company is well positioned for earnings improvement as the economy strengthens, and that it continues to pursue acquisitions such as Rheodyne, Halox and Wrightech, which were acquired in 2002 for $74.9 million. The company is named as a defendant in asbestos-related personal injury lawsuits along with five subsidiaries. Components were sourced from third-party suppliers, and settlements and legal costs have been largely covered by insurance, though the company cannot predict future insurance availability. No provision has been made in the financial statements, and management does not currently believe these claims will have a material adverse effect.
- 2001-ADec 19, 2002
Idex Annual Report (Amendment), Year Ended Dec 31, 2001
IDEX Corporation's 2001 annual report describes a year of record orders and sales but lower profitability. New orders totaled $713.4 million, 2% above 2000, though excluding foreign currency and five acquisitions, orders were 9% lower. Sales rose 3% to $726.9 million from $704.3 million, with acquisitions contributing 13% and base business sales declining 9%. Net income fell 48% to $32.7 million from $63.4 million, and diluted EPS was $1.05. Excluding a $11.2 million restructuring charge, net income was $39.8 million and diluted EPS was $1.28. The company cut its workforce by 15 percent, affecting almost 600 employees, and states that annual savings from these actions will exceed the total charge. The filing emphasizes cash generation and balance sheet strength. Cash flow from operations rose to $107.3 million, and free cash flow of $86 million was a record that the company says has exceeded net income every year since 1988. Total debt fell to $291.8 million from $241.9 million in 2000... (note: total debt rose from $241.9 million to $291.8 million), while total assets reached $838.8 million. Goodwill of $454.6 million was tested under SFAS No. 142 with no impairment recorded on January 1, 2002. Management describes the outlook for 2002 as highly uncertain given very small order backlogs, but says the company is well positioned for recovery based on reduced costs, Six Sigma, global sourcing, eBusiness initiatives, and continued debt reduction.
- 1994Mar 20, 1995
Idex Annual Report, Year Ended Dec 31, 1994
IDEX Corporation, a Northbrook, Illinois-based designer and manufacturer of fluid handling and industrial products, reported record 1994 results. Net sales rose 29% to $399.5 million, income from operations increased 37% to $68.7 million, and net income rose 33% to $33.6 million, or $1.72 per share (adjusted for the three-for-two stock split). Operating margin improved to 17.2% of sales from 16.2%. The company's Fluid Handling Group accounted for 69% of 1994 sales and 75% of profits, while the Industrial Products Group accounted for 31% of sales and 25% of profits. Acquisitions of Signfix (November 1993) and Hale Products (May 1994) contributed about 14% of 1994 sales, and international sales were 32% of the total. The balance sheet expanded substantially with acquisitions. Total assets rose to $371.1 million from $259.0 million, and long-term debt increased to $168.2 million from $117.5 million, largely from the $91.6 million Hale acquisition financed under the bank credit agreement. Working capital was $82.0 million and the current ratio was 2.2 to 1. Operating cash flow was $52.5 million in 1994. The Board authorized a three-for-two stock split, effected as a 50% stock dividend payable January 31, 1995, and instituted a quarterly cash dividend of $.14 per share on post-split shares. Management stated it expects new records in sales, net income and earnings per share in 1995, citing the full-year inclusion of Hale Products and planned debt reduction. The company reported no material pending legal proceedings and no environmental matters that management considers material. Backlog is described as not materially significant, at about 1-1/2 months of sales.